THERAPY DOSSIER · th-575e2b4aa08e

Siponimod

Drug · S1P receptor 1/5 modulator; sequesters lymphocytes in lymph nodes.

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: S1P receptor 1/5 modulator; sequesters lymphocytes in lymph nodes.
Target: CHEMBL4333 (S1PR1/Edg-1)
Injury models: Haemorrhage/shock
Reported indication: Secondary progressive multiple sclerosis (active disease); S1P1/5 modulator (Mayzent, approved 2019)
First approval: 2019
Development stage: Approved for SPMS; intracerebral-haemorrhage use investigational
ChEMBL record: CHEMBL2336071 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Mayzent; BAF312
Note: Not recorded

Clinical trials 3

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03338998 ↗Injury indicationPHASE2completed

Trial title not recorded

Intracerebral Hemorrhage

Enrolment: 32 · Results not recorded

NCT01904214 ↗PHASE1completed

Trial title not recorded

Renal Impairment

Enrolment: 16 · Results not recorded

NCT05826028 ↗NAcompleted

Trial title not recorded

Secondary Progressive Multiple Sclerosis

Enrolment: 368 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32963692 ↗2020Reported benefit

A Sphingosine-1-Phosphate Receptor Modulator Attenuated Secondary Brain Injury and Improved Neurological Functions of Mice after ICH

MouseHaemorrhage/shockUnspecifiedC57BL/6Nn = 134 mice total, divided into sham and ICH groups with treat…Intraperitoneal0.3 mg/kg (low dose) or 3.0 mg/kg (high dose) in 0.5% DMSOFirst dose 30 minutes post-ICH

Model: Collagenase-induced intracerebral haemorrhage (ICH)

Low-dose Siponimod, particularly with multiple administrations, significantly reduced ICH-induced brain oedema at 72 hours, attenuated ventriculomegaly at 10 days, improved neurological motor function and working memory, and reduced CD3+ lymphocyte brain infiltration; high-dose Siponimod was ineffe…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…